Adaptive Biotechnologies Corp. ADPT

What this company does

Adaptive Biotechnologies Corporation applies proprietary technologies to read the genetic code of a patient's immune system, and uses those insights to develop and commercialize clinical products and services tailored to individual patients. As of December 31, 2025, the company had 624 full-time employees, of which 94 held medical or doctoral degrees. For its TCR-antigen binding and immunoSEQ testing services, the company operates laboratories in Seattle, Washington and South San Francisco, California. In 2024, the company reorganized around two main businesses: the MRD business, covering clinical assessment of minimal residual disease in lymphoid malignancies, and the Immune Medicine, or IM, business, focused on applications and products connecting the adaptive immune response to disease. The MRD business is built around the clonoSEQ clinical diagnostic test, offered to clinicians, and the clonoSEQ assay, offered to biopharmaceutical partners for drug development. The IM business sequences, maps, pairs, and characterizes T cell receptors and B cell receptors at scale using the company's proprietary capabilities. The company was incorporated in the State of Washington on September 8, 2009 under the name Adaptive TCR Corporation, changed its name to Adaptive Biotechnologies Corporation on December 21, 2011, and acquired Sequenta, a San Francisco, California-based company that was also developing an NGS test for MRD, in January 2015.

Written from the business description in Adaptive Biotechnologies Corporation's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.